-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AxGainxIX+p0wRNagX0WFIc/pKDkgjiS+fl8ckIfsywuKyTnMKw7gp5Y2Zx6xyr5 3VVIkEjVtRGcOkT4UjbGdQ== 0001193125-06-162521.txt : 20060804 0001193125-06-162521.hdr.sgml : 20060804 20060804170855 ACCESSION NUMBER: 0001193125-06-162521 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20060804 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20060804 DATE AS OF CHANGE: 20060804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRIAD HOSPITALS INC CENTRAL INDEX KEY: 0001074771 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 752816101 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14695 FILM NUMBER: 061006636 BUSINESS ADDRESS: STREET 1: 5800 TENNYSON PARKWAY CITY: PLANO STATE: TX ZIP: 75024 BUSINESS PHONE: 9727892732 MAIL ADDRESS: STREET 1: 5800 TENNYSON PARKWAY CITY: PLANO STATE: TX ZIP: 75024 FORMER COMPANY: FORMER CONFORMED NAME: TRIAD HOSPITALS LLC DATE OF NAME CHANGE: 19981207 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


FORM 8-K

 


CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) – August 4, 2006

 


TRIAD HOSPITALS, INC.

(Exact Name of Registrant as Specified in Charter)

 


 

DELAWARE   001-14695   75-2816101

(State or Other Jurisdiction

of Incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

5800 Tennyson Parkway

Plano, Texas

  75024
(Address of Principal Executive Offices)   (Zip Code)

(214) 473-7000

(Registrant’s telephone number, including area code)

 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 2.02 Results of Operations and Financial Condition.

On August 4, 2006, Triad Hospitals, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2006. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

99.1 Press Release issued by Triad Hospitals, Inc. on August 4, 2006.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, Triad Hospitals, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

TRIAD HOSPITALS, INC.
By:  

/s/ REBECCA HURLEY

  Rebecca Hurley
  Senior Vice President and General Counsel

Date: August 4, 2006


EXHIBIT INDEX

 

Exhibit No.  

Description

99.1   Press Release issued by Triad Hospitals, Inc. on August 4, 2006.
EX-99.1 2 dex991.htm PRESS RELEASE Press Release

Exhibit 99.1

LOGO

FOR IMMEDIATE RELEASE

 

Investor Contact:   Media Contact:
Laura C. Baldwin   Patricia G. Ball
Vice President of Finance and Investor Relations   Vice President of Marketing & PA
214-473-3969   214-473-3752

laura.baldwin@triadhospitals.com

  pat.ball@triadhospitals.com

Triad Reports Second Quarter Results

PLANO, TX (August 4, 2006) – Triad Hospitals, Inc. (the “Company” or “Triad”) (NYSE: TRI) announced consolidated financial results for the three and six months ended June 30, 2006. For the three months, the Company reported revenues of $1.4 billion; earnings before interest, taxes, depreciation, amortization, and other items (“adjusted EBITDA”) of $186.7 million; net income of $60.1 million; income from continuing operations of $60.0 million; diluted earnings per share (“EPS”) of $0.69; and diluted EPS from continuing operations of $0.69. Results for the three months include additional compensation costs of $6.9 million pretax, or $0.05 per diluted share, due to stock compensation expense recorded with the January 1, 2006 adoption of Statement of Financial Accounting Standards (SFAS) 123(R), “Share-Based Payment.”

On a same-facility basis compared to the prior year three-month period, inpatient admissions increased 0.2%, adjusted admissions increased 1.5%, and inpatient surgeries increased 3.8%. Patient revenue per adjusted admission increased 8.1%, patient revenues increased 9.7%, and revenues increased 9.6%. Revenue growth rates reflected the impact of the Company’s self-pay discount policy; excluding self-pay discounts (which reduced net revenue relative to what it would have been without the discounts), the Company estimates that patient revenue per adjusted admission would have increased 8.6%, patient revenues would have increased 10.2%, and revenues would have increased 10.1%. Same-facility results included facilities owned for the full second quarter of both years.

For the three months, the Company reported a provision for doubtful accounts of $128.2 million, or 9.3% of revenue. Excluding the self-pay discounts of $50.2 million (which reduced both provision for doubtful accounts as a percent of net revenue and net revenue relative to what they would have been without the discounts), the Company estimates that the provision for doubtful accounts would have been 12.5% of revenue.

For the three months, cash flow from operating activities was $36.7 million, or $185.3 million excluding cash interest payments of $50.4 million and cash tax payments of $98.2 million. During the quarter, the Company spent $115.1 million on capital expenditures plus $12.2 million for the acquisition of an additional 21% interest in Massillon Community Health System, LLC, a venture in which Triad acquired an interest in February 2006. The acquisition increased Triad’s ownership interest to 80% from 59%. On June 22, 2006, construction began on Cedar Park Regional Medical Center, a new 75-bed hospital in Cedar Park, Texas, that is owned by an entity having an affiliate of Triad and Seton Health System as its partners. On July 7, 2006, construction began on a 270-bed replacement hospital for Gateway Medical Center in Clarksville, Tennessee; an affiliate of Triad acquired an 80% interest in a venture formed to own the existing hospital in February 2006. During the quarter, Triad paid debt principal of $0.3 million and received proceeds of $9.3 million from the issuance of common stock.


At June 30, cash and cash equivalents were $276.0 million, and the Company had $577 million available under its $600 million revolving line of credit, which was reduced by $23 million of outstanding letters of credit. Long-term debt outstanding was $1.7 billion, and stockholders’ equity totaled $3.1 billion.

For the six months, the Company reported revenues of $2.7 billion; adjusted EBITDA of $383.7 million; net income of $143.2 million; income from continuing operations of $127.9 million; diluted EPS of $1.65; and diluted EPS from continuing operations of $1.48. Results for the six months include additional compensation costs of $13.7 million pretax, or $0.10 per diluted share, due to stock compensation expense recorded with the January 1, 2006 adoption of SFAS 123(R).

On a same-facility basis compared to the prior year six-month period, inpatient admissions decreased 0.1%, adjusted admissions increased 0.9%, and inpatient surgeries increased 5.0%. Patient revenue per adjusted admission increased 8.4%, patient revenues increased 9.3%, and revenues increased 9.1%. Revenue growth rates reflected the impact of the Company’s self-pay discount policy; excluding self-pay discounts (which reduced net revenue relative to what it would have been without the discounts), the Company estimates that patient revenue per adjusted admission would have increased 9.8%, patient revenues would have increased 10.7%, and revenues would have increased 10.4%. Same-facility results included facilities owned for the full six months of both years.

For the six months, the Company reported a provision for doubtful accounts of $248.9 million, or 9.1% of revenue. Excluding the self-pay discounts of $95.4 million (which reduced both provision for doubtful accounts as a percent of net revenue and net revenue relative to what they would have been without the discounts), the Company estimates that the provision for doubtful accounts would have been 12.1% of revenue.

For the six months, cash flow from operating activities was $132.9 million, or $308.5 million excluding cash interest payments of $58.0 million and cash tax payments of $117.6 million. The Company spent $233.4 million on capital expenditures and $49.2 million on acquisitions during the six months. The Company paid debt principal of $1.0 million and received proceeds of $21.9 million from the issuance of common stock.

For 2006, Triad reiterated its guidance for diluted EPS from continuing operations of approximately $2.81-2.93, as well as its guidance for diluted EPS from continuing operations excluding stock compensation expense of approximately $2.99-3.11.

Because of an increase in the provision for doubtful accounts and information systems conversion costs, the Company expects 2007 diluted EPS to grow approximately 10-13%; however, beyond 2007, the Company expects to return to annual EPS growth in the mid-teens percent range.

Triad will conduct a conference call at 9:30 am Eastern Time (8:30 am Central Time) today, August 4, to discuss these results. To listen to the call, please call 877-704-5386, confirmation code 1945442. International participants, please call 913-312-1302, confirmation code 1945442. This conference call will be simulcast on the Internet via the Triad website at www.triadhospitals.com. A recorded replay of the call will be available for 14 days at 719-457-0820 or 888-203-1112, confirmation code 1945442.

Triad, through its affiliates, owns and manages hospitals and ambulatory surgery centers in small cities and selected larger urban markets. The Company currently operates 52 hospitals (including one under construction) and 12 ambulatory surgery centers in 16 states with approximately 9,490 licensed beds. In addition, through its QHR subsidiary, the Company provides hospital management, consulting, and advisory services to more than 180 independent community hospitals and health systems throughout the United States.


This press release contains forward-looking statements based on current management expectations. Numerous factors may cause results to differ materially from those anticipated in the forward-looking statements. These factors include, but are not limited to, (1) the highly competitive nature of the healthcare business, (2) the efforts of insurers and other payers, healthcare providers and others to contain healthcare costs, (3) possible changes in Medicare, Medicaid and other government programs that may limit reimbursements to healthcare providers, (4) changes in Federal, state or local regulations affecting the healthcare industry, (5) the possible enactment of Federal or state healthcare reform, (6) the ability to attract and retain qualified management and personnel, including physicians and nurses, (7) the departure of key executive officers from Triad, (8) the successful implementation of Triad’s new information technology system, (9) claims and legal actions relating to professional liabilities and other matters, (10) fluctuations in the market value of Triad common stock, (11) changes in accounting standards, (12) changes in general economic conditions or geopolitical events, (13) future acquisitions, joint venture developments or divestitures which may result in additional charges, (14) the ability to enter into managed care provider arrangements on acceptable terms, (15) the availability and terms of capital to fund the expansion of Triad’s business, (16) changes in business strategy or development plans, (17) the ability to obtain adequate levels of general and professional liability insurance, (18) potential adverse impact of known and unknown government investigations, (19) timeliness of reimbursement payments received under government programs, and (20) other risk factors described in our Form 10-K and other Company filings with the Securities and Exchange Commission. Many of the factors that will determine the Company’s future results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and, therefore, actual results may differ materially. Readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. This release contains certain financial information not derived in accordance with generally accepted accounting principles (GAAP), including adjusted EBITDA; the Company believes this information is useful to investors and other interested parties; such information should not be considered as a substitute for any measures derived in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies; reconciliation of this information to the most comparable GAAP measure is included as an attachment to this release. All references to “Company”, “Triad”, and “Triad Hospitals, Inc.” as used throughout this document refer to Triad Hospitals, Inc. and its affiliates.

 

-30-


Triad Hospitals, Inc.

Consolidated Statements of Operations

For the Periods Ended June 30, 2006 and 2005

Unaudited

(Dollars in millions, except for earnings per share)

 

     For the three months ended  
     2006     2005  
     Amount     Percentage     Amount     Percentage  

Revenues

   $ 1,378.1     100.0 %   $ 1,167.3     100.0 %

Salaries and benefits, including stock compensation expense of $6.9 in 2006

     553.9     40.2 %     482.9     41.4 %

Reimbursable expenses

     12.3     0.9 %     13.0     1.1 %

Supplies

     234.5     17.0 %     196.0     16.8 %

Other operating expenses

     272.3     19.8 %     216.1     18.5 %

Provision for doubtful accounts

     128.2     9.3 %     90.2     7.7 %

Depreciation

     55.5     4.0 %     52.0     4.5 %

Amortization

     2.1     0.2 %     1.5     0.1 %

Interest expense

     23.7     1.7 %     27.0     2.3 %

Refinancing transaction costs

     —       0.0 %     8.4     0.7 %

ESOP expense

     3.1     0.2 %     3.9     0.4 %

Gain on sales of assets

     (0.5 )   0.0 %     (0.8 )   (0.1 )%
                            

Total operating expenses

     1,285.1     93.3 %     1,090.2     93.4 %
                            

Income from continuing operations before minority interests, equity in earnings and income tax provision

     93.0     6.7 %     77.1     6.6 %

Minority interests in earnings of consolidated entities

     (5.2 )   (0.3 )%     (2.7 )   (0.2 )%

Equity in earnings of unconsolidated affiliates

     9.8     0.7 %     9.6     0.8 %
                            

Income from continuing operations before income tax provision

     97.6     7.1 %     84.0     7.2 %

Income tax provision

     (37.6 )   (2.7 )%     (32.8 )   (2.8 )%
                            

Income from continuing operations

     60.0     4.4 %     51.2     4.4 %

Income from discontinued operations, net of tax

     0.1     0.0 %     7.7     0.6 %
                            

Net income

   $ 60.1     4.4 %   $ 58.9     5.0 %
                            

Basic income per common share:

        

Continuing operations

   $ 0.70       $ 0.64    

Discontinued operations

   $ —         $ 0.10    
                    

Net

   $ 0.70       $ 0.74    
                    

Diluted income per common share:

        

Continuing operations

   $ 0.69       $ 0.62    

Discontinued operations

   $ —         $ 0.10    
                    

Net

   $ 0.69       $ 0.72    
                    

Shares used in earnings per share calculations

     86,146,846         79,936,308    

Shares used in diluted earnings per share calculations

     86,994,726         81,947,276    


Triad Hospitals, Inc.

Reconciliation of Non-GAAP Financial Information

For the Periods Ended June 30, 2006 and 2005

Unaudited

(Dollars in millions)

 

     For the three months ended  
     2006     2005  
     Amount     Percentage     Amount     Percentage  

Revenues

   $ 1,378.1     100.0 %   $ 1,167.3     100.0 %

Salaries and benefits

     553.9     40.2 %     482.9     41.4 %

Reimbursable expenses

     12.3     0.9 %     13.0     1.1 %

Supplies

     234.5     17.0 %     196.0     16.8 %

Other operating expenses

     272.3     19.8 %     216.1     18.5 %

Provision for doubtful accounts

     128.2     9.3 %     90.2     7.7 %

Equity in earnings of unconsolidated affiliates

     (9.8 )   (0.7 )%     (9.6 )   (0.8 )%
                            
     1,191.4     86.5 %     988.6     84.7 %
                            

Adjusted EBITDA (1)

     186.7     13.5 %     178.7     15.3 %

Depreciation

     55.5     4.0 %     52.0     4.5 %

Amortization

     2.1     0.2 %     1.5     0.1 %

Interest expense

     23.7     1.7 %     27.0     2.3 %

Refinancing transaction costs

     —       0.0 %     8.4     0.7 %

ESOP expense

     3.1     0.2 %     3.9     0.4 %

Gain on sales of assets

     (0.5 )   0.0 %     (0.8 )   (0.1 )%

Minority interests in earnings of consolidated entities

     5.2     0.3 %     2.7     0.2 %
                            
     89.1     6.4 %     94.7     8.1 %
                            

Income from continuing operations before income tax provision

     97.6     7.1 %     84.0     7.2 %

Income tax provision

     (37.6 )   (2.7 )%     (32.8 )   (2.8 )%
                            

Income from continuing operations

     60.0     4.4 %     51.2     4.4 %

Income from discontinued operations, net of tax

     0.1     0.0 %     7.7     0.6 %
                            

Net income

   $ 60.1     4.4 %   $ 58.9     5.0 %
                            

Basic income per common share:

        

Continuing operations

   $ 0.70       $ 0.64    

Discontinued operations

   $ —         $ 0.10    
                    

Net

   $ 0.70       $ 0.74    
                    

Diluted income per common share:

        

Continuing operations

   $ 0.69       $ 0.62    

Discontinued operations

   $ —         $ 0.10    
                    

Net

   $ 0.69       $ 0.72    
                    

Other data

        

Gross patient revenues

   $ 4,071.0       $ 3,280.7    

Revenue deductions

     2,748.2         2,162.9    
                    

Net patient revenues

     1,322.8         1,117.8    

Non-patient revenues

     55.3         49.5    
                    

Revenues

   $ 1,378.1       $ 1,167.3    

(1) Adjusted EBITDA is defined as earnings before interest expense, income taxes, depreciation, amortization, ESOP expense, gain on sales of assets, refinancing transaction costs, minority interests, and discontinued operations. Adjusted EBITDA is commonly used by lenders and investors to assess leverage capacity, debt service ability and liquidity. Many of Triad’s debt covenants use adjusted EBITDA, or a modification of adjusted EBITDA, in financial covenant calculations. Adjusted EBITDA is used by management to evaluate financial performance and resource allocation for each facility and for Triad as a whole. Adjusted EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and items excluded from adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to net income, cash flows generated by operating, investing, or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. Because adjusted EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.


Triad Hospitals, Inc.

Consolidated Statements of Operations

For the Periods Ended June 30, 2006 and 2005

Unaudited

(Dollars in millions, except for earnings per share)

 

     For the six months ended  
     2006     2005  
     Amount     Percentage     Amount     Percentage  

Revenues

   $ 2,747.3     100.0 %   $ 2,320.4     100.0 %

Salaries and benefits, including stock compensation expense of $13.7 in 2006

     1,111.4     40.5 %     942.2     40.6 %

Reimbursable expenses

     26.0     0.9 %     26.6     1.2 %

Supplies

     471.7     17.2 %     386.1     16.6 %

Other operating expenses

     525.4     19.1 %     424.8     18.3 %

Provision for doubtful accounts

     248.9     9.1 %     195.9     8.4 %

Depreciation

     108.8     4.0 %     99.1     4.3 %

Amortization

     3.6     0.1 %     3.0     0.1 %

Interest expense

     47.4     1.7 %     53.5     2.3 %

Refinancing transaction costs

     —       0.0 %     8.4     0.4 %

ESOP expense

     6.1     0.2 %     7.2     0.3 %

Gain on sales of assets

     (0.6 )   0.0 %     (0.5 )   0.0 %
                            

Total operating expenses

     2,548.7     92.8 %     2,146.3     92.5 %
                            

Income from continuing operations before minority interests, equity in earnings and income tax provision

     198.6     7.2 %     174.1     7.5 %

Minority interests in earnings of consolidated entities

     (10.0 )   (0.4 )%     (6.3 )   (0.2 )%

Equity in earnings of unconsolidated affiliates

     19.8     0.8 %     19.7     0.8 %
                            

Income from continuing operations before income tax provision

     208.4     7.6 %     187.5     8.1 %

Income tax provision

     (80.5 )   (2.9 )%     (72.4 )   (3.1 )%
                            

Income from continuing operations

     127.9     4.7 %     115.1     5.0 %

Income from discontinued operations, net of tax

     15.3     0.5 %     10.0     0.4 %
                            

Net income

   $ 143.2     5.2 %   $ 125.1     5.4 %
                            

Basic income per common share:

        

Continuing operations

   $ 1.49       $ 1.46    

Discontinued operations

   $ 0.18       $ 0.13    
                    

Net

   $ 1.67       $ 1.59    
                    

Diluted income per common share:

        

Continuing operations

   $ 1.48       $ 1.43    

Discontinued operations

   $ 0.17       $ 0.12    
                    

Net

   $ 1.65       $ 1.55    
                    

Shares used in earnings per share calculations

     85,958,229         78,921,143    

Shares used in diluted earnings per share calculations

     86,665,173         80,690,327    


Triad Hospitals, Inc.

Reconciliation of Non-GAAP Financial Information

For the Periods Ended June 30, 2006 and 2005

Unaudited

(Dollars in millions)

 

     For the six months ended  
     2006     2005  
     Amount     Percentage     Amount     Percentage  

Revenues

   $ 2,747.3     100.0 %   $ 2,320.4     100.0 %

Salaries and benefits

     1,111.4     40.5 %     942.2     40.6 %

Reimbursable expenses

     26.0     0.9 %     26.6     1.2 %

Supplies

     471.7     17.2 %     386.1     16.6 %

Other operating expenses

     525.4     19.1 %     424.8     18.3 %

Provision for doubtful accounts

     248.9     9.1 %     195.9     8.4 %

Equity in earnings of unconsolidated affiliates

     (19.8 )   (0.8 )%     (19.7 )   (0.8 )%
                            
     2,363.6     86.0 %     1,955.9     84.3 %
                            

Adjusted EBITDA (1)

     383.7     14.0 %     364.5     15.7 %

Depreciation

     108.8     4.0 %     99.1     4.3 %

Amortization

     3.6     0.1 %     3.0     0.1 %

Interest expense

     47.4     1.7 %     53.5     2.3 %

Refinancing transaction costs

     —       0.0 %     8.4     0.4 %

ESOP expense

     6.1     0.2 %     7.2     0.3 %

Gain on sales of assets

     (0.6 )   0.0 %     (0.5 )   0.0 %

Minority interests in earnings of consolidated entities

     10.0     0.4 %     6.3     0.2 %
                            
     175.3     6.4 %     177.0     7.6 %
                            

Income from continuing operations before income tax provision

     208.4     7.6 %     187.5     8.1 %

Income tax provision

     (80.5 )   (2.9 )%     (72.4 )   (3.1 )%
                            

Income from continuing operations

     127.9     4.7 %     115.1     5.0 %

Income from discontinued operations, net of tax

     15.3     0.5 %     10.0     0.4 %
                            

Net income

   $ 143.2     5.2 %   $ 125.1     5.4 %
                            

Basic income per common share:

        

Continuing operations

   $ 1.49       $ 1.46    

Discontinued operations

   $ 0.18       $ 0.13    
                    

Net

   $ 1.67       $ 1.59    
                    

Diluted income per common share:

        

Continuing operations

   $ 1.48       $ 1.43    

Discontinued operations

   $ 0.17       $ 0.12    
                    

Net

   $ 1.65       $ 1.55    
                    

Other data

        

Gross patient revenues

   $ 8,149.8       $ 6,502.2    

Revenue deductions

     5,513.5         4,284.3    
                    

Net patient revenues

     2,636.3         2,217.9    

Non-patient revenues

     111.0         102.5    
                    

Revenues

   $ 2,747.3       $ 2,320.4    

(1) Adjusted EBITDA is defined as earnings before interest expense, income taxes, depreciation, amortization, ESOP expense, gain on sales of assets, refinancing transaction costs, minority interests, and discontinued operations. Adjusted EBITDA is commonly used by lenders and investors to assess leverage capacity, debt service ability and liquidity. Many of Triad’s debt covenants use adjusted EBITDA, or a modification of adjusted EBITDA, in financial covenant calculations. Adjusted EBITDA is used by management to evaluate financial performance and resource allocation for each facility and for Triad as a whole. Adjusted EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and items excluded from adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to net income, cash flows generated by operating, investing, or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. Because adjusted EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.


Triad Hospitals, Inc.

Consolidated Balance Sheets

Unaudited

(Dollars in millions)

 

    

June 30,

2006

   

December 31,

2005

 
Assets     

Current assets

    

Cash and cash equivalents

   $ 276.0     $ 310.2  

Accounts receivable less allowances for doubtful accounts of $338.4 at June 30, 2006 and $292.8 at December 31, 2005

     888.1       800.2  

Inventories

     140.0       130.0  

Deferred income taxes

     33.4       31.8  

Prepaid expenses

     39.1       41.1  

Discontinued operations assets

     —         67.6  

Other

     106.3       93.0  
                
     1,482.9       1,473.9  

Property and equipment, at cost:

    

Land

     198.1       182.3  

Buildings and improvements

     1,908.2       1,739.3  

Equipment

     1,590.2       1,449.1  

Construction in progress

     188.6       226.3  
                
     3,885.1       3,597.0  

Accumulated depreciation

     (1,115.5 )     (1,012.8 )
                
     2,769.6       2,584.2  

Goodwill

     1,330.0       1,301.6  

Intangible assets, net of accumulated amortization

     72.4       71.7  

Investment in and advances to unconsolidated affiliates

     235.4       204.8  

Other

     107.2       100.7  
                

Total assets

   $ 5,997.5     $ 5,736.9  
                
Liabilities and Equity     

Current liabilities

    

Accounts payable

   $ 206.8     $ 197.5  

Accrued salaries

     131.3       126.8  

Current portion of long-term debt

     13.8       7.7  

Current income taxes payable

     7.1       17.1  

Discontinued operations liabilities

     —         3.1  

Other current liabilities

     183.4       163.1  
                
     542.4       515.3  

Long-term debt

     1,693.7       1,695.8  

Other liabilities

     173.3       167.8  

Deferred taxes

     184.1       201.9  

Minority interests in equity of consolidated entities

     288.1       228.4  

Stockholders’ equity

    

Common stock

     0.9       0.9  

Additional paid-in capital

     2,374.8       2,331.6  

Accumulated other comprehensive loss

     (1.6 )     (1.6 )

Unearned ESOP compensation

     (8.6 )     (10.4 )

Accumulated earnings

     750.4       607.2  
                

Total stockholders’ equity

     3,115.9       2,927.7  
                

Total liabilities and stockholders’ equity

   $ 5,997.5     $ 5,736.9  
                


Triad Hospitals, Inc.

Consolidated Statements of Cash Flows

For the Periods Ended June 30, 2006 and 2005

Unaudited

(Dollars in millions)

 

     For the three
months ended
   

For the six

months ended

 
     2006     2005     2006     2005  

Cash flows from operating activities

        

Net income

   $ 60.1     $ 58.9     $ 143.2     $ 125.1  

Adjustments to reconcile net income to net cash provided by operating activities:

        

Income from discontinued operations, net of tax

     (0.1 )     (7.7 )     (15.3 )     (10.0 )

Provision for doubtful accounts

     128.2       90.2       248.9       195.9  

Depreciation and amortization

     57.6       53.5       112.4       102.1  

ESOP expense

     3.1       3.9       6.1       7.2  

Minority interests

     5.2       2.7       10.0       6.3  

Equity in earnings of unconsolidated affiliates

     (9.8 )     (9.6 )     (19.8 )     (19.7 )

Gain on sales of assets

     (0.5 )     (0.8 )     (0.6 )     (0.5 )

Deferred income tax provision (benefit)

     (6.0 )     11.2       (11.7 )     4.9  

Refinancing transaction costs

     —         8.4       —         8.4  

Non-cash interest expense

     0.8       1.1       1.6       2.3  

Non-cash stock compensation expense

     6.9       0.4       13.7       0.6  

Excess tax benefits on stock compensation

     (0.2 )     —         (1.2 )     —    

Increase (decrease) in cash from operating assets and liabilities

        

Accounts receivable

     (137.5 )     (91.1 )     (321.7 )     (255.5 )

Inventories and other assets

     (12.0 )     14.8       (22.5 )     25.6  

Accounts payable and other current liabilities

     (71.3 )     (36.4 )     (31.9 )     17.6  

Other

     12.2       0.8       21.7       16.1  
                                

Net cash provided by operating activities

     36.7       100.3       132.9       226.4  

Cash flows from investing activities

        

Purchases of property and equipment

     (115.1 )     (88.3 )     (233.4 )     (188.6 )

Distributions and advances (to) from unconsolidated affiliates, net

     (3.6 )     8.7       (9.6 )     12.8  

Proceeds received on disposals of assets

     11.9       35.9       102.6       36.5  

Acquisitions, net of cash acquired

     (12.2 )     (155.3 )     (49.2 )     (155.3 )

Other

     —         —         (0.1 )     —    
                                

Net cash used in investing activities

     (119.0 )     (199.0 )     (189.7 )     (294.6 )

Cash flows from financing activities

        

Payments of long-term debt

     (0.3 )     (462.9 )     (1.0 )     (483.8 )

Proceeds from issuance of long-term debt

     —         520.0       —         520.0  

Payment of debt issue costs

     —         (6.4 )     —         (6.4 )

Proceeds from issuance of common stock

     9.3       29.6       21.9       89.8  

Excess tax benefits on stock compensation

     0.2       —         1.2       —    

Contributions from (distributions to) minority partners, net

     0.5       0.8       0.5       (0.7 )
                                

Net cash provided by financing activities

     9.7       81.1       22.6       118.9  
                                

Change in cash and cash equivalents

     (72.6 )     (17.6 )     (34.2 )     50.7  

Cash and cash equivalents at beginning of period

     348.6       124.9       310.2       56.6  
                                

Cash and cash equivalents at end of period

   $ 276.0     $ 107.3     $ 276.0     $ 107.3  
                                

Interest payments

     50.4       48.0       58.0       54.9  

Income tax payments

     98.2       56.8       117.6       59.8  


Triad Hospitals, Inc.

Operating Data - Same-Facility (1)

Unaudited

 

     For the three months ended June 30,  
     2006     2005     Change  

Volume Statistics (2)

      

Number of hospitals

     47       47     —    

Licensed beds

     8,216       8,048     168  

Admissions

     78,612       78,417     0.2 %

Average length of stay (days)

     4.7       4.7     0.0 %

Inpatient surgeries

     32,124       30,950     3.8 %

Outpatient surgeries

     72,117       70,373     2.5 %

Outpatient visits (excluding outpatient surgeries)

     980,348       953,568     2.8 %

Outpatient visits (including outpatient surgeries)

     1,052,465       1,023,941     2.8 %

Adjusted patient days

     634,504       627,069     1.2 %

Adjusted admissions

     136,120       134,144     1.5 %

Rate Statistics (2)

      

Patient revenue per adjusted patient day

   $ 1,933.0     $ 1,782.5     8.4 %

Patient revenue per adjusted admission

   $ 9,010.2     $ 8,332.7     8.1 %

Revenues (millions)

      

Inpatient % of patient revenues (2)

     54 %     54 %   0.0 %

Outpatient % of patient revenues (2)

     46 %     46 %   0.0 %

Patient revenues (2)

   $ 1,226.5     $ 1,117.8     9.7 %

Non-patient revenues (3)

   $ 53.1     $ 49.5     7.3 %

Revenues

   $ 1,279.6     $ 1,167.3     9.6 %

(1) Same-facility operating data include facilities owned and operated in the full second quarter of both years. They:
  Include Deaconess Hospital (322 beds), acquired April 2005;
  Exclude Medical Center of South Arkansas (166 beds), owned 50% and reported on an equity (non-consolidated) basis;
  Exclude Trinity Medical Center (560 beds), acquired October 2005;
  Exclude Gateway Medical Center (206 beds), acquired February 2006;
  Exclude Massillon Community Hospital (268 beds), acquired February 2006;
  Exclude facilities reclassified to discontinued operations.
(2) Volume statistics, rate statistics, and patient revenues:
  Exclude the QHR hospital management, consulting, and advisory services subsidiary.
(3) Non-patient revenues:
  Include the QHR hospital management, consulting, and advisory services subsidiary;
  Include other sources.


Triad Hospitals, Inc.

Operating Data - Same-Facility (1)

Unaudited

 

     For the six months ended June 30,  
     2006     2005     Change  

Volume Statistics (2)

      

Number of hospitals

     46       46     —    

Licensed beds

     7,894       7,735     159  

Admissions

     154,763       154,983     (0.1 )%

Average length of stay (days)

     4.7       4.7     0.0 %

Inpatient surgeries

     62,032       59,051     5.0 %

Outpatient surgeries

     138,565       134,183     3.3 %

Outpatient visits (excluding outpatient surgeries)

     1,898,156       1,852,313     2.5 %

Outpatient visits (including outpatient surgeries)

     2,036,721       1,986,496     2.5 %

Adjusted patient days

     1,237,615       1,226,461     0.9 %

Adjusted admissions

     264,391       262,162     0.9 %

Rate Statistics (2)

      

Patient revenue per adjusted patient day

   $ 1,925.5     $ 1,777.2     8.3 %

Patient revenue per adjusted admission

   $ 9,013.2     $ 8,314.4     8.4 %

Revenues (millions)

      

Inpatient % of patient revenues (2)

     54 %     54 %   0.0 %

Outpatient % of patient revenues (2)

     46 %     46 %   0.0 %

Patient revenues (2)

   $ 2,383.0     $ 2,179.7     9.3 %

Non-patient revenues (3)

   $ 105.6     $ 101.6     3.9 %

Revenues

   $ 2,488.6     $ 2,281.3     9.1 %

(1) Same-facility operating data include facilities owned and operated in the full six months of both years. They:
  Exclude Deaconess Hospital (322 beds), acquired April 2005;
  Exclude Medical Center of South Arkansas (166 beds), owned 50% and reported on an equity (non-consolidated) basis;
  Exclude Trinity Medical Center (560 beds), acquired October 2005;
  Exclude Gateway Medical Center (206 beds), acquired February 2006;
  Exclude Massillon Community Hospital (268 beds), acquired February 2006;
  Exclude facilities reclassified to discontinued operations.

 

(2) Volume statistics, rate statistics, and patient revenues:
  Exclude the QHR hospital management, consulting, and advisory services subsidiary.

 

(3) Non-patient revenues:
  Include the QHR hospital management, consulting, and advisory services subsidiary;
  Include other sources.


Triad Hospitals, Inc.

Operating Data - Pro Forma for Acquisitions & Divestitures (1) 

Unaudited

 

     For the three months ended June 30,  
     2006     2005     Change  

Volume Statistics (2)

      

Number of hospitals

     50       50     —    

Licensed beds

     9,250       9,082     168  

Admissions

     85,818       86,261     (0.5 )%

Average length of stay (days)

     4.7       4.7     0.0 %

Inpatient surgeries

     34,963       33,467     4.5 %

Outpatient surgeries

     77,378       74,870     3.3 %

Outpatient visits (excluding outpatient surgeries)

     1,097,537       1,084,924     1.2 %

Outpatient visits (including outpatient surgeries)

     1,174,915       1,159,794     1.3 %

Adjusted patient days

     691,271       687,588     0.5 %

Adjusted admissions

     147,448       146,647     0.5 %

Rate Statistics (2)

      

Patient revenue per adjusted patient day

   $ 1,913.5     $ 1,759.3     8.8 %

Patient revenue per adjusted admission

   $ 8,971.1     $ 8,248.7     8.8 %

Revenues (millions)

      

Inpatient % of patient revenues (2)

     54 %     54 %   0.0 %

Outpatient % of patient revenues (2)

     46 %     46 %   0.0 %

Patient revenues (2)

   $ 1,322.8     $ 1,209.6     9.4 %

Non-patient revenues (3)

   $ 55.3     $ 51.5     7.4 %

Revenues

   $ 1,378.1     $ 1,261.1     9.3 %

(1) Pro forma operating data:
  Include Deaconess Hospital (322 beds), acquired April 2005;
  Include Trinity Medical Center (560 beds), acquired October 2005, on a pro forma basis as if owned since January 1, 2005;
  Include Gateway Medical Center (206 beds), acquired February 2006, on a pro forma basis as if owned since January 1, 2005;
  Include Massillon Community Hospital (268 beds), acquired February 2006, on a pro forma basis as if owned since January 1, 2005;
  Exclude Medical Center of South Arkansas (166 beds), owned 50% and reported on an equity (non-consolidated) basis;
  Exclude facilities reclassified to discontinued operations.

 

(2) Volume statistics, rate statistics, and patient revenues:
  Exclude the QHR hospital management, consulting, and advisory services subsidiary.

 

(3) Non-patient revenues:
  Include the QHR hospital management, consulting, and advisory services subsidiary;
  Include other sources.


Triad Hospitals, Inc.

Operating Data - Pro Forma for Acquisitions & Divestitures (1) 

Unaudited

 

     For the six months ended June 30,  
     2006     2005     Change  

Volume Statistics (2)

      

Number of hospitals

     50       50     —    

Licensed beds

     9,250       9,082     168  

Admissions

     175,569       177,706     (1.2 )%

Average length of stay (days)

     4.7       4.7     0.0 %

Inpatient surgeries

     69,632       66,249     5.1 %

Outpatient surgeries

     152,598       146,370     4.3 %

Outpatient visits (excluding outpatient surgeries)

     2,194,896       2,175,980     0.9 %

Outpatient visits (including outpatient surgeries)

     2,347,494       2,322,350     1.1 %

Adjusted patient days

     1,412,661       1,405,749     0.5 %

Adjusted admissions

     298,217       298,072     0.0 %

Rate Statistics (2)

      

Patient revenue per adjusted patient day

   $ 1,875.5     $ 1,738.6     7.9 %

Patient revenue per adjusted admission

   $ 8,884.2     $ 8,199.5     8.4 %

Revenues (millions)

      

Inpatient % of patient revenues (2)

     55 %     54 %   1.0 %

Outpatient % of patient revenues (2)

     45 %     46 %   (1.0 )%

Patient revenues (2)

   $ 2,649.4     $ 2,444.0     8.4 %

Non-patient revenues (3)

   $ 111.3     $ 107.2     3.8 %

Revenues

   $ 2,760.7     $ 2,551.2     8.2 %

(1) Pro forma operating data:
  Include Deaconess Hospital (322 beds), acquired April 2005, on a pro forma basis as if owned since January 1, 2005;
  Include Trinity Medical Center (560 beds), acquired October 2005, on a pro forma basis as if owned since January 1, 2005;
  Include Gateway Medical Center (206 beds), acquired February 2006, on a pro forma basis as if owned since January 1, 2005;
  Include Massillon Community Hospital (268 beds), acquired February 2006, on a pro forma basis as if owned since January 1, 2005;
  Exclude Medical Center of South Arkansas (166 beds), owned 50% and reported on an equity (non-consolidated) basis;
  Exclude facilities reclassified to discontinued operations.

 

(2) Volume statistics, rate statistics, and patient revenues:
  Exclude the QHR hospital management, consulting, and advisory services subsidiary.

 

(3) Non-patient revenues:
  Include the QHR hospital management, consulting, and advisory services subsidiary;
  Include other sources.
GRAPHIC 3 g67598img001.jpg GRAPHIC begin 644 g67598img001.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`?P+&`P$1``(1`0,1`?_$`-H``0`"`@(#`0$````` M```````*"P@)`PW>#EQL4(CU+76%U<8&?"1H=%28LWS<>Z[Z#MQ&K)RE6PI+&;[^=C+!%*G=3J`CN*"R"0[")@"0GDOY4Z;?\` M9=5N6^1A[^W5:L8]^,5<\8]\4S$>&<3FTEYC=?U;7NNGVK;YC&W>BNN8X?-F M,/5CFD=\)^6..>:O&G&O(K&KE,(B]1/G)N%,L59[4+FR-Z-;*?)]T=R/H&7( MHGN8`%5'N+>10!'2G4^Q7^F-]O;'K:9B]8KF*9F,(JB)F(F/3A\O[SO MNWV]98JCFFF,8\>[].QED`[@`_9`!#]@==&[KT\30-`T#0-!\Q=;&SIM/MEP MD#D28U2L6"R/5%!$I"M(&*=2K@3&[P`4A$FIA-Y>P-!6W8W\5=UL^0F0Y2B\ M<.-F#R32MY$=*IHHHG3(JY.FDB*@_)OM MH,K2=:WQ41Q$"],1MN`;]O#?.9>SR>4U^`!T'766O$%^)/P+1IC)V:N`]%Q7 MCNOF8$G+M>^*^8JW68DTF\1CX\KZ8D\C-V;<7;UP1),!-N8Y@`.W08O8_P#% MR=93*UVK.-\:89XP7R_W.6;0-3IM5PGD.:L=BFGAA*UC(B*9925=OGJX@/=( M0HF';09U?VU'BI=Q#^S%9B(;;[<.\WCMOVAVAD$0[0_P:#Y2Y]>+Q/&.:[)V M^[]-^(KE8@VZCV8FY'ASG@L=&,D""JN\D'"%[4]$9H)%$RBI^Z0A0$1,`!OH M-HGAS.O'RHZJ6?.0&&>4$%A>#-0L1PN1Z"&+*G/UAXZ41MZ5$-`T#0/V>P/LC\F@ZMR7G'"N% MF4;)9DR]C#$L?,N3LH9]DV^U:AM)=XF!!4:1:]IE8M.0RT#0-`T#0-`T#]GL#[(_)H,..;G/?BST[\4QN:.6F1CXVH$U:6U*A)% MO6K':WDS:WD3*3;6$8Q-7BY=^JY6BX9TL`F(5("HCN8!V`0BT\N?&A\5*5&2 M4/PPX^Y+S;;E$521URRX5MBW'+5<1$J3L89F[F[Q-MBF`#^8,C%&,'9YPH^0 M-G72OZAO+7J!='Z[OVR!3)J&,)3!W;TP[_`)_L>0;G#W2XVJ]T8MP```[1\FW9H.70-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0 M-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-!QJ?)]O[F@X]`T#0-`T M&O7J;<[:CT^.*5^S?.*1SVYKM#U3#U0=*D*XN&3)M!5"`:`W\X"JT1$'`S^1 M.4`!-F@(;@8Y=_5="=,ZSJ[J.UM-J*HT?/$W*XC.FF..'9PC+'CZGE^K=\TV MQ[1SNS0MUNNU&\:^YJ]3[-VJ9X9]N,<6^?P_'4D#A_P`CQX_Y1GA8\>N2;BL=Y9.9..JML\^LH5%A$V0!+&2AB[%`QFRYQ_>S".I_.[HO2]0].6 M]XV^U_\`>6(F9JIC.Y3,>U$]\Y8QAV^$MG^4_5MS;-V_I&KN?R5R<,9G.,\L MN$,F5V3) MQOL=.2M-7?5*+!$=P$%U)&;2*38=^^(;:#15X/#BG`8GZ<%BY+O8!NWR!R"^(H;I\^+CSC@:MLDJIC7/ M5%RI,T2%:@"$02CN!OE$VX]O:81T'ZT#0!\@]NVX"&_V-_E^3R:"HN\3WE[+V1^L%R2JF M3I.0^!F?,?W^7L$UCW#F=F$%A]W-J.7J,/%V&G-)FU5""'N+/5IS;C[!=(@L<8_G:?BW(C>EU9DC%UF%FKC4 MFKJPE@H=J1-I#Q[Z7;JN0;(E*DFHL;N`!1``";]X0X-^C=3P_P#J"SJ(?,(3 M4*(#]H0T$G@$@`XFW'83&.!``H`!SB(G-OMON<1[=N[]O0?TI!W2`&^XAY1[ MH%W'8-Q[I>P-Q^30$1';*LLZUW48 M>=0+EI+KU&5K(W[=KNGT M=ZFYH;-?+151.--5.4XTSW3^G8T\?;UM:Y8F+GOXC&;E.$QW9Q\'!K2F_P`* MIC"<'D1$0`-Q#;82F*82G*8IBG*8IBB!B&(;%S"YCCEQ6,70"ZDH\U>-#;$63;&1[R(XX1L;7+.H]7W?W_'H( MD9U#(!/.%`[QV@1'ZME3`)NZ[0*J8=UPU!GSCZ!KZ3WN==9IJC9]15S4UX3R MQ7.,U4Q5PG'.?#..Y+_RQZPM[[M$Z+55T_U6W&')C'-RQ$83AQ_U2!`$!WV$ M/*._S=NM0T3,U53^QEA/?Z&Q[QAGW'%HQ M%F>BUW)>,KHR386NC6QB22KUA9MW2#]%I)L5!*FX1(\:IJ%`P[`=,H^4`T'Y MP]AO%V`,;U?$6%Z+6L9XRI;-1C5*/4(U**KL$T<.5WKAO&QZ0F*V35>NE%3= MHB90YC"(B.@[+T$>CQ2GZE?E#_KW#OYT:MH*X[H6_KA>G?\`I.4/_2'&@NB1 M\IO\\W[1=!^1\@[?8'[/V/F`1_O!H,9[#PYXO6_D#5>6-FP3CB9Y)4N*;0M2 MS9)5U!?(4!%-&\DU:,6,[NFZ1;)-IETF4@@/=*X.&VQA#0=[25KJT!(0$'.V M6OPDU:7+EE5X:7F8R.E;(\:-SO7;2`CW3E)U,N6K0AE5"-B'.1(!,(``;Z#W M3EZS9-W+QX[;-&C-([AVZ=+I-VS5!,HG.NY75.1)!$A"B(G,(%``$=^S0=,0 M?)SC99[,6EUKD+@ZPW$ZPMB5.#RQ0Y:R'<@82&;DA&$\O)'<%.40$@)B8!#R M:#N[OE`PE[P`8LE':OHRBR)G+& M7'[BAQ4PO'\=^(,/1Z[C7%TD]B9.!J%@8V:28VU5-LYFG-[E4'\C)N;K(%%) M5T=^IZ48G2814:V(*CB1DGC9BQ03`!$3K.W2B3=(@`':)C``:#'V5YC\0X)V+":Y4<<8 ME\43%.SD30=C;AN(".VWEW[-NS?MWV^0=`$0*` MB/8`=HB/R;>7?]C0`,4P")1`0#RB`[@'S[^3;Y_)MH.A[ARGXQ8]?'B[[R,P M52I--3S2D;:LM4*`D$U`-W!*HRDYYLY3$#]@[E#8=!V+3,BX]R7%_7>.+Y2\ M@PI3E`TO2+1!VN+`=QV`7\$^?M=]RC^Z^3056?BW^[_;,Y,[NW_\(X'WV^S^ M"2F^_P`^@F">$-_4W4_](+.W\L:=LVO^D[?5'W^ M[E7$<8IP_P`"*= MV)BY,3QQ?K5[&:#+;@UR[O\`P6Y-8XY'8^<.%U*C($8W"LD4,5M=\>RRQ4+A M47I!,!52OXX15:F-N9%^DFJ`@)=>+ZSZ9T?6.R:C;=;\^FB9M]DQ5&<8>.+U M'3'4.IZ=W6QK[4S&->%>/=.4X^KXEJU@O,=`Y"8DH&;L6SB-BH&3:Q%VJLR: M1B"8S&10!06CHI3G%"1C%^^V=(F'OHN$3D-V@.OGCK=JUNRZ^_MVNCEO6KDQ MAW8=WAW3W)M;;K]+NFCMZ_23$VKE$3CZL_@=LZX[GF@:!H&@:!H(]'BE/U*_ M*'_7N'?SHU;05QW0M_7"]._])RA_Z0XT%T2/E-_GF_:+H/R.VP[B(!L/:'E# ML\H?.&@A6]9/F;XESBG6TVW3#&%RCB>-J^0,FPF-W4U]4U. MUW-G;)JP/H5==%PW!TY;QA$VZRP`(%+VB$/GA#U'\F..JGQ(YE062\EPV M+,NLKA<[K>IV:M;R"K*<7))2;>O0953,8LBZ;H"(LV*""!U#D#N@&^P2LV6* M>IOXG6QR&2[%DJV]/GI.M9J0:XHIL45ZM?L\,(]XJR-:W\0W=PI+HNN4@^<> MR*X03%3=)DWX8N MR`1L,E7'*\Y5DV[(T);$4'!&JPD;K(/&PI"8_G2#H-Q71XZB77HY8=/%G5>' M%8P7GB^KK.G3WD[`+N7+ MI9=PX M4&<#3;;%%8G5%PK%:@Z\+5*P9*M[=LHB[?1T8Y?HMF;$BB?IKPX]XX)IJ;A" M>X2DE!U=E%6Q7DC?[&5HDF^N#[+:<`Y> MO`3V6>H0]?KK2(:$75$3E3$BP%#8.\;M$0CH=:[P]5EZ2E`9\X>"><\NR.'* M_:(>,O$7(3CJ$REAYS.NRL:W9XNYTDU=-.UA69%-HLJH@W_Y(&KRD[@#-$WYM.U7!M5&17L_CN]NBD3)/3[>" M(L_CY-7_`,TY3;*H+^.O$^ M0R/B+"]_N"-!Q%Q^P_*OXK(63C2C[T.(7R59H)=M*2TC+D."B\>DX1B&*7>* MSC41^MX;'& M2[4S1KEV<-$S*C!#;ZO'04>C]9&)W`;3<5)1RXF[JQDR?2`(1W5?Y/PNH!P91&'=SZ)R.#I-3G9* M=X%6YO-*%``L1_"&_J;J?^D%G;^.8702?-!RD\GV_N!H/WH&@:!H&@:!H&@: M!H-$G44X']6;*$_E++_`;JOW3",%QQ)BUYBILXB*S&QB]>BLHFK MLO<*^:QRT:J]%R^8RJ:;IZ<@^;0*4Q`KX,Q]=7K^Y2QG9 M)&I7>FV&AX<;2L%.1BOFUVZH%QRH@Z:KIB59LY0.JV=ME$UT%%$5"','6OO& M_6O_`._K)7XF8=_]-]!8;^'XZTU;ZKG'`:UDA]$0?,[!<-%QV;ZJV!M'I7Z% MW2C8C.%0BT@22+"6=R!4IAJW("<--'%+N)M7+`50D&Z#H/DWBC)6;,,6O&^( M^0-TXO7Z=5@E83->/J[4K7::H6*GHV6D$&,%>(^3KCU&?CF2L>X\\EWR-W)S M)&(H!3`$+3K)TKQ$W2[Q*ZY.8YZJ]ZY,<;H67B8B^RX8.D"JLR)J"J4,;.C#D/Q&G6`7NEYA^IK;\# M<<,;S[:IVG,-@Q9BJVR,Y,57S`V%Z;<'=(JK)26M,M3K)`5N>B9R5@H-LX>FCG#%B+A!N,?6PZ]W+/D%B+C5BOG]:TGE_1V)IF4;8IDW#%@"GWZA&ZQ@#R%'R:"1RXX.^,G12%1/ MJ$X9=G`2@"+>[4`JI@$=A$!=<:FR.Q0[1W.`[>3?0="95P/XU+&,0]FF&=Y7 M*S1@F=9=OBJZ<6)B7.D0!$QV4%9:A4YJ34V#<$FS=5BS]'R)B7&M0M,2J(CYL7D).XK8OTT7!0[R2O<\VL MF('(8Q1`1"=9X6KFAR@YT=/S*67.667IW-&183E=>Z'$6>P1E9BG;"H16+<- MS>_'3E#R0Q-'UGB7S3MW"3 M*$#+O9UK>ZWCNFY)C;:7ZE?,F-3MT/;43*M*^:372<'W000^M'=_$9=(56JY$5ZF%[ MS_QBOLZ:K0.8X7$^)ZG*U:XG;.Y%C3LDU%2E3Z$!(3$6Q76C7C:0>,WX-5RB M+=4A43!H$]XWZU__`']9*_$S#O\`Z;Z#8ITL.I-UX>J-S*H/$BF]3>V8O-98 M>T6RSWZP8\Q+-HUJH4V+/*33N-KK2A1SBQSC@12;M&8.6I#JK`=59)(BARA8 M>\(^+');C4A>_P"L7S[RYSA>VU"K$@CY+QKBW'$?C]:#&>&97K3+'D6W>.?P MK&5;@Y*_=NP1"/2\UW1,J)PSST$8?JL\1NL5BG%')[EQPVZN>50:4%MD[.2' M&.WX9PLVA8C&L,,S=92AX^R&TK3J44=4JJ(*-XE.48N5I,&B::[HBR@JB$9? MH_),?T#(>5K#G*[U.M,(:T9>M MD/!5^QY"EVI3`ZLLO"5ELT@(MV^.;<46J94B```&X[B(:=NM=UUL$=(:@Q," M>';YAY69'A74IB["#64^KF<=#$668$R)E*6;D7=UVCI22"B+5%(@OYMR@J@U M\VFDZ=M0AN\<);Q#7B0;M(_P## MSRT1)\J9F.Y]\,CRC*#0R%;YF?R562>?.=M'Q2N8W,=&YGQ1:WJ0$3:)V=*0 MAU5?WMJD\,4VP=8"^(IFG#]IC)R]Y1XYX;\=AIF:[ ME6>'93&=57JCAWRZ7?=VM=/[9=W'551'NZZ631.!0`S@=XV>>O0E-[3T]6[;:]NW$TW\,<:L[_QS7UXV:ICW7#V<..?&<<8X\.].D(83`40'O@D;7%RB_A,Q[N?TXN761D-`T#0-`T$>CQ2GZE?E#_KW#OYT M:MH*X[H6_KA>G?\`I.4/_2'&@NB1\IO\\W[1=!XT&J[K>M6ZW2.ZA!5DB*%' MC1?CB0^YB"9)LBNF/<,(E^@JF40[/D#05)?3-Q!1.0O4"X;X2RI%*3V.)>.F):/AG&S)\ZDT*?081M`Q`R3XQ1>2+E M-L`*O7[KN%[ZRQSJ&`A0$=@`-!7.>--233ZAW'DY"%*=3BI%%4.`!WS@GDB[ ME3`YO*8"`/9OY-]!MZ\$I_T9L#T)N/W6!E,0VK)>4L MC8<,4Y3%$` MT&=_3VX"8(Z;?&>J\7\`,90:E`NY">GK-95F[NWWRX3:@'FK7:7;1HR:G>O" MH)))())$1:MD4T2!W2`(AG`8")IF%0P)I%*(G4.8"%*7]T8QS"`%V^SH-%/B M`(H=A.)OH62;'$0 M`#)K1S]1,P;;"`Z"7%XU'F!8:?C#C'PEJDL[8L\M2D[F_*+9JMW"RU:H[Q"O MT.$>D*3OK1RMICW=O+H++-,OFB%(&X=W?Y M1-OOO]\)MQ-Y?ET'A4A3@4I@W#OE'RB`[AOMVE$!^X/RZ"I^\6VW;H=9G)XH M((H"MA3!"RXHI$3,NN:H&(9=P8A0,NN8B90$Y]S"!0#?8`T$PGPAOZFZG_I! M9V_CF%T$GS0;N!O)'&G*'C[9%*]D3&TR1X1NL9<\#;J\ZV;V2BW"/160^MZE;(HQVKQ` M3%.4IBK(G2<)(K)A.T7-DQ/DZ,:M M5+10;&5,J1CJQZKDB[%YYM-.3C'#=VF4I%@(4,]]!JPZX$8PE^D/U%FLDU2= MMTN*&6I--)8H'(1_"5U>9BG0`("`*LI1@BL0?*4Z8"':&@UW^$EC&##HN8@= M,VJ2#B;S#G^3E54R@4[U^ED60ADW2X@`"=4D7$-D0$>WN(E#R!H)+^@Z'Y3L MFTEQBY'1SQ,%6C_`^7V3I(=ME6SK'UA073'\N/%\9,4D[-*/8!HXFY7#DD_13!U* M5;([9LJT0:K'%%E,JMGA-O-JE5#7EX+HAD^EQF@ARF("9)"M\=.HC3(,OIM?=CQOSB]9MR^<5A9 M0\G:\/6*1\T4H@C&2Y9R*6AN`%(&@KX=!80>"GYO-7M7Y,=/>UR MA"R<'))\FL/-G"I`4=0LL2"HV7(9IWQ*;S<1*-J^_11)WA,,B\5V`"&'03V- M!A)U'>'=8Y\<(N1W%"S-V1U,KXXF&%.DGQ$S)UO)D,4EAQE:2*'*8R/X/7N* M8.5!*)140(HF(]TYMPH_K16IZEV6Q4ZTQ;N#L]3G9:M6.%?I"B^B)Z"?N(N7 MBWJ)OI).X^0:J)*%'M*<@AH,X^EIS(D>`G/[C#RI;KN4X'&^2HQ'(C5J)Q4D M\46Y)Q3 MSE8J38K$%4X/EXD]+2C9*L<,6.RCS&FE>0%F670%.10H3QN$)AB%45,4ASQQJ0U" M=0((?O:MA7#Y1T$CRSV.(I]:L-NL#LK"!JT'+6.;?'#?+W._*S),@]=3.6;Y+S$+&/'!UTJC1&BPQN/Z-&E, M8Q48RG4]HS8)`7;O^8%0_>44.8P6NOAO`Q:7HN<(/YJ1AQCQHUI&Z#%@W!Q_ M.D.1+<.1PG/-?O\`]<%L_GP_?_WST4$>[^]>:T&\70?&9$QW1,N46VXQR?4H M"^8\OD#)5>Y4VTQC:8KUDK\NV.TD8F6C7B:C=TT=(*"`@8-P'8Q1`P`(!5C\ MU>E$XZ4?7DX04"FA*2'&W,W+OC7D[CI.RBJCQXQK1^0%(:63&A M:3D7B-Q^NMBJE@F(S+E,BOPOY%5LYXFY$G(9Y(H/&S7'C=?T&/*L7N+*+KN4 MQ,4Y!U(KRWW+I/R[MSK.J_>VM]O6XKM1%JNJ(M5>S&<1A$_.QCCCA'9#3'7^ MU=2]=4S1TY-NYM-J8BOZRFFJ:L?^F9B>[/N:5!\.MU7C;;X+I_9OM_\`.#'W M^UM;9N>=_E[7'/.IO<_=[FY^IJR/)?K6FGGIMVOEWA[6HO\W_`(+GZE:?)WK3"/JK7\2W_N/=T^J__073O^<. M/O\`:VKOSU\NOQ.H_@7/U*_D[UI^ZM?Q+?\`N/=T^J__`$%T[_G#C[_:VGYZ M^77XG4?P+GZC\G>M/W5K^);_`-Q[NGU7_P"@NG?\X\B[9OD"'*8!`>\4H>01UQ-9YV>7.LLU:2_>O5Z*Y1,5Q-BYV\,L,Y MPQ9]+Y4]::'56]18MVZ==35C1AC1"3Z-ECO(99PS33N4.*;\R!3F%HY.L@;8Z0AJ M(W66T:?;-RHO;7%=73^K^LL7)IFF>6&>$SGBSU`=PW[?MZ\O5733.'&?#-Z2BJ*XQIX>.3SJY6 M)QS@T5-`T#01Z/%*?J5^4/\`KW#OYT:MH*X[H6_KA>G?^DY0_P#2'&@NB1\I MO\\W[1=!XT&K;KZ>7S`><7X.LMLJ]\R5?\`T2.8VEF9@5&92JE4CHADY.!U M#F\V]5>%^D(?8$`A]]$8>]U=.GL;M[>3^-!'O#N(_P#Q$W:(]@;B&@W7^-`< M2:G4KPNW=*J_5S;BE5#111*($3!?(%_]-%(0^^`[@@;_`#AH-KO@@TF@<>^> MK@H)`^6S+AY%8P&`51:HTBU*M2'[=P3*JNMW=_*/>^QH)R'VP'YP$!#^^'9H M/R;]S_G!H*H+Q<'ZYG)?Y$,#_P#"2N@F!^$-_4W4_P#2"SM_',+H)/F@Y2>3 M[?W`T'[T#0-`T#0-`T#0-`T#00F3#M9H4Y3%*_104`.\0H@%W#"S438X:)L,#(M) M>"GHQA-0LM'KD)" MI6%:)UE^9T7@Z52?PTM<*];KZQ:-R)1U>S)<*=`V/*T*P!@8]O%0\6R1+]%)I'Q[1-),H=A M2$`-!U3R@I\UD/C1R(H%<3.K8;S@S+=/@4DP,*BDU9J!8(6+3(!1`PG.^>I@ M&W;N.@H?UT%VJZS9RBJW/BSD&=:S&3L$2TLI%G:RX(MX]Q?L8SIT'J53 MO(1C9))P51!5A,-VZ2+I,#I-G34+//I[]7C@?U,JLUE.,V9X=U?$X\CZRX,N MZC6HYLJ!BIF4=ED:.]=J+3<4AE9.)$>P'7>W*`;,]!J`ZM/3BLG/E; M@9;<=O*5#Y%X>\Z,)R4>DYQ'7)UN_RQ5(5S%0@:#15UXNI$3@KQ==TC'LVFUY'8W5?_'-BKHTF>OO1,>BG"<_7P1-N MA#U(UN#7*I"DY%F7"7';D9(Q=6R0H^L] M1L>\19UUR9T.IJGGXS$93A,8]O-$>G&>"R3;J).4B+)*)K)*$(HDJB8BB2J2 MJ95$E$U"[D.10A@,`AN`E$-0DCWM$UZ>K*Y3EGE\/H[4LN;W\6[U.=JJ(GX? M\'.3NB4!'R[?Y)?\6N'$:FF.69SAFKLTS5/!^MB_W%+_`(M/YA;[F#8O]Q2_ MXM/Y@]S!L7^XI?\`%I_,'N8:R^K%SXKG3UXDV_+`+L'>5K,1:D8.K+H4C'F< MA2K90&DHNW,8!/"5!N)I%Z<0$H%1(F([J%W]YY?=*:KJW?K6AN1/W"BNFN[5 MPPHC+#U\/1C+R?6/4>EZ4V>YKJIC[[53--J.,S,_XT0T;8J[.1JY'+"7A)=JD]CI!H MLF)B*-W358IR&#R@.H(W=!=T&JKTFHIFF]15-,Q/&)C*83#^\6M7H:-;I9QM M5Q$^I](']W[&N)9QPJBKC%CQ2GZE?E#_KW#OYT: MMH*X[H6_KA>G?^DY0_\`2'&@NB1\IO\`/-^T70>-!JUZW/ZI#J#_`*,N0O\` M0":"J3Z+WZU[IY_I98@_XI8:"ZW'RC^R/[>@\:#R'E#]D/V]!69>-0_6&<=O MT58W\Y-WT&W?P2G;PSYCA_\`4S7?S90F@BJ>)`Y>Y$Y4=5SDU$6&;=.J%QRN MDEQ_Q97046+%UZ%H:_U;87;1F=0R23ZS6U)X[=K`4!7`4BF^@F0H!-Q\*1P7 MP[@?ILXXY2QU>B)'.G*LUCM=NR$JV;N9]A3H.VSE8K%"BWZB9W$3"LB09W3E M!$Q`%_+*.8'4KRT)=L`VE^BB8 M?1)AI(_A[3R/50*)2D?-7'81;F`.W0=*>"JY+PM.Y):L M;U3)='9++`F$I8<3R,JQG&34AQ#OO`K=R.Z[I=S&1:*#ML7L"QY`-@`/L`'] MP;?('R:!MN)0_P#M!]W050/BX-_[9G)>X;?_`"0P-M\X#45!WT$P/PAOZFZG M_I!9V_CF%T$GS0SP\98:W9(F1@;#`3;%M*0TY!S#-:/EH>6C7J2S.1C M)-@X41<(*D.DLDZ6^?1RMAR'DI3A'G:POUL8R@>E2! M\/7%P1Q*2.$K5(*BJKYMHW36(F:+0'X`VZ<>[1W'?+5@=$3"07=N3^;C,5Y!?*%3F2B)6T5)' M3D_WE(\FHJ$\SK6&*?I&=1@Y#%.0_#_-IB'*(&*8IJ3)B4Q3!N!BF`=P$/+H M->/A,?U*F"_RI<@_SL6+024-!TCR9_Z;^0/Y$(KE9@(V2\\^EIB3=&(W9,6J8;G4.(%#0 M61_-KQ3/2OXN8_GWN(7>80CG84_&N%VDPZKSZ8\V!&"EKRG(1+>DP%>* MY4*+E1HXDI$J13"BS6,`!H(FOAN^1^3^7OB()/DSF>62F5%/X1\1^07*V\B@I!81QG8;BA&N%O1 MPL5E2;A'TJHHJ[E$CNXW)\PBT1W#95V705B%2Z2^4N7O1CYN]97)!YVP\AY[ MD0_S755U5'@#;<,U6P6)GR7MYF0"+59*6N=S>R/G3@8[5"C*E2$".3`8(S^@ MEH^#_P";P\>>HE/<7[1,>A8]YGT=6LQR#EP9)@WS/C-"6MV/'9N^;S*:TQ7E MI^'3*``=P\?M";CW2AH+/#)F1*EB''-^RO?I5&"HV,J7:,@7*:<"`(Q-6IT( M]L,_(J]XQ0$C.*CU5!#<-^[MH(37A=L2?#7D?='UL-)PC-1=C@_+=N>KR=GQY9DVY!3A:U8YU==]6 M7)@3:F1<&C0V5:$%P$6#0>]K%ILU)L$/;:98IVHVJO/D)2`LU8EY"`L$')MC M=]M(P\U%.&DE&OFY^TBR*A%"#V@(:"77TQ_%W(I^=3V60,J@ M=-4X97:!H&@XU/D^W]S0<0]@"/V`U;7CR3AQPDG@Z^RIDNEX:QQ=LKY&G6M< MHN/:U,VRU3;Q4$T(^(A62KITH`B=/SBZ@$\VDF`]Y58Y2%`3"`:Y>@TNHW'6 MV=#I*>:]WZ.]K=55A113,YSW>GOX*J_J&^'D:;E5%451,Q$3CQ[L_E6$/AV>I,IRGX]+<8=K^Y:FY,ZJS$1$3..4 M998YY?)X0DD`&P`'V.SR;>3YMQUIN,<,^+;7-5VS+SH8SWFAC/>]1,2T7!Q4 MI-3$@VBHJ(9.9&5DGRY&S*-CV*)W+U\\<*F(F@V:MDC'4.80`I"B.^KIHOW; MEO3:>B:KMVKEC#CGEEX]WBLO5T:*FO6WZOJ8IQSX*Q/K']1&2ZA7+.?LE?D7 M?\PN*%92@X-B%!.1%W"MW?FIZ^.&XF$H2%ZD6OGBB(=XC!)N3?8!#4\O*GHB MGI+IZ+>KHHJU]^*:JZL,\Z?FS,YX1$X>K'BAOYD]55=1[U--JJK[I8F8IC'+ MCQAJ;W$XD*'! MKB9GFFY^W/&>WX4VKPS?4D-::U(=/?+0-@U'6B)BF)GYTYSZ9;LHIY8P['[UBV0 M3;-U"%`QSJ&``+N$+O@1R28\/N:O&#E!)Q3B>B<&YHI&0IJ&8F3!])P4',(* MSC)B*Q@2]-7B3+`CWA`!4VW$/+H+6+`GB.^D5R-LM`HU"Y..6.0LG6.`J-4H M5KQADFOS[FSV5^C'1,(LJM65X--XY?N2("H#TZ'>$-C["`Z#>:;<0,`%W'80 M[H#W=S>00`1VV`1\@Z"*EU[NM1T]X'@9S0XH4SD35LD\E[G5K-@9/%E.9R\I M*5ZVN9=O"V4+6]4C4X>&:UMNV=`L8ZXF%9,$R`)C`(!6Z\%<]PO%OF7Q:Y&3 MS5R^KV$L[XSR-8F3'NJ/7?G#;@VVJ3GEGR#HF#"7[ZV"F%N3F1(M8S0!6 MAYGZL;1K!^NX!@5^@"FQ0V%8H>4P:"KW\2YU$^/W48Y[UZ]\9;"ZN>*<4X<@ M,6LKPXB9&%;6V?;V*R6">D(AG+MF4D,*V4F$D$%E4B>D"0YRAW!+N&S'PI?5 MRX8<$J!R8X_\M\I-,**9&R%5LGT.\3\7-OJG*>AUI2MSM?D9"$82@PT@V%DV M61,X332735.4#]XH!H-='B#>(#4W).[]2?BQ,H9VX)<\>M7TQ3J MOE3TU2&R71[,\3:I&@':EPCW+EFHZ*D1T"YDRB)TA*`9S^'X\27CKI]X:2X; M\R*Q=)+!\+8Y:?Q3E:AL`L,SCQ*RN3R,Y5++5#.6SJ8K0RZJCMJX9'.Z;"NL M045"B3NA*5M7BINBW7*R,\RY'76VNQ1.JE5ZOA7)I[*HH)3'(A_\:K\+#MUC M#L7=5X5,!'M$.T=!IRY&\Y^J1XBS&>5L!]._C7.\<^"(U2QJY,S?F(A4+)G- M.#8+2;+&$(_;MUHD@VR09HM_JR"]/6[ZH"\>H(`8@A"FX89?7X4\[N.>9[]7 MIF-6XZ\A*+:+_67C95A8HYK3;4V3N<0K'*D3=(RS-FW%OK2):,VT%;=E'!7/#H6\ZZ58[7797&>7<+79*TXPR(@T M>N\:91A&:SEN9_7)HJ?U?8:K:X-11K(,Q4!RDDNHBLF10-M!89<%_%+=,GDW MC6"?9YRS'<1LSLHMO^&M$RDC,$J1I@B*:;YU2K\SCWL-+P;EP!CMDG*C=\FF M(%.F.W>,'JN:?BE>`.%8)>H<0IB8YU\C;&!8S'&/L005C<4]>QOP40C?KZXF MBT%I%NDX,0QV,2@^>.0_>R>:W$Y0KU>L%$\]%N71LI=1IF,)R-Y`8TIV9SU$ MQT4CT+'UA5F(BD4=:';G62JRM=CJ^9,(L555VB9B`N;T@RH`$O3PK_5HX*8$ MX(_U1N07("G84R_!Y[N,O6HB]G>1;&[Q&2U8`\$-@:!H&@:! MH&@:!H&@:"#EU9O_`'8O2#_)]A+\[/(#03C=!CYRHXNX6YG8"R5QIY!5%M<\ M593KZ\%8(Q02(2#!8#D=1%DKDB*2JD+:ZQ+((OXQ\F43M7B"9P`P`)1"FXZK M?3)S-TJ^6%JX\Y/2=3U/?>D6C"&6$X]1I!Y8QBY>*HQ3/_3?R!_(CE;_@.>T%#KH,^.EI@K&G)SJ)\.>/N8X5U8L6 MY?SO2*+>X-E,2D`[DZY./_1I!HWFH1TQEHU51,>Q5NLFH7Y#!H)X?-KP:'#* M^X]L$MP;R-DK`N8H]@[=5BL9'M*N2\/65\B3SK:#FUY&.'(%7^L%">9"31D9 M$C4#]\S%QW>Z(1]/"ZXIR#@KKUM,,Y7K$C3,EXMQ_P`FJ)>JK*D*5]!6>LU] MQ$R\>J9(RB#@B3QL;S:R1SH+I"51,YTS%,(6I&@:!H&@CG^*&X+#S-Z6>3+5 M6849/+'$E[_6/HQFKC)5ULY'Z&PZ"5]A3B9B#"7$:@\+(2OM9/" MU*PBQP2ZA'[?G$ M^R<&^9O(_BA:`B(M87$W%XM0C(2ZY MFB!(C_YA5^PG58VG2*`)B8YI5PGY2CH-^?1\X4M^G[TYN,/&IS'(L+O7Z"TM MV7#$*7SSK,&0SGN60R.%PW%V6$GI<\4V4'M]!CT"[`!0``V7Z!H/CL@X]HF6 M*1:,:Y.I];O^/KM#/:];Z7;X=C8*S9(.03%)Y%S,/)H.&+]FN0>TBA!`!`!# M80`0"!GU5/!V.7#^S9GZ6EH9D0=*O9=]Q+R?/>BE:'.(*BPPYE.86.D9N8XB M"$59U4_-!N/UN8.X@4(,^=>/6#.(2%0R%6I.M2X(^< M.FE(,DY!!)*5B'8IB+=ZU.LT2.H>.D"IF>1#T2N&X@8#D.%S7 MQ$Y18OYJ<:<-Y29PG/AWN$XB4HB!1-V#V% M[!$=O(`AV@.K:;E,Y595=RDS5-<41'LS.&/=X^I"8\3+U'R6*P,>GCB6=!2$ MKJT3;>2\I&+B9-[8$@1DJ;BI5=$PIF2BD5B2LFCOVKG:IG`.X\GULXSC.'A'9'JC)'N]-J:HFS&$ M+7)D[1CZ>1=. MXPRRB3*UU-X(-K;398B?8K%V.&$Z)M_O%034+]-,HAXWJWI_3=5[7=VS5X11 M73A1,QC-$]E4>,<8\7?]-[Y>V'=Z-PT_-]WIJB:J(G#'TS_EPE:L\8^26-N6 M."L:9_Q-(IR5*R97V\U'%\^15U%/=S-YBO2H)EW;S,#)HJMG"1BE,!TA'8`$ M-X`=1;-J>F]^U&QZZ8FJQ+6_[38W6Q3-' MOK<531,Q-5$]M-4QEC#(#?Z7=^;SS1F\&$2AN M!1'66J:*(YJYP<>[75;^;3-7H15/$G]2'^9O%+/@YBF>,AE/-\067S`^BW7= M>T[#IUQ*6!4<(""C.5R(Y2!$Q!,50L6100#NJE'6_/(KHJ-VUU74FZT'SL>&%&.7C,]L-2^;G5]&U;7.SZ?&=1=IC&J*HCEB9X3'Z1\*""4 MO<^@7;N%``(`!ML`;@`;!]$H`4`#8.S4R;--44\TS'+/".Z([$3YF9]JJ)YY MSE^@\H:OKPY)QX82MQPS??XORE><'Y(HV8,93CBO9`QM98RWU.9:F.11G+PR MY7*9%>X8HK,'J13H.D1^BNV5.F(;&UTVZ;9I-QV._I-SIB_9N43%,=V.6>.. M+MNGMSO[9NE&IT\S3A5$SGV+4?IY\V:+SVXL8XY!4T6[23F&98/(M425[[ND M9'ATT6]IKCI$P`LF@D[.#AF8X!YYBLDH`CN.OG5U;L.KZ1WBO;M3CSRLO+ MMY?GT'G^QWZ5O_8#Q9_Y157^!:#W]4Z4?36H=HKMUI/![C75[=4IJ.L=9L<- MBVML)>"G8ER1W&2T:\0:%5;/6+I,JB9P'FO?[79+Q=^#_&RU6ZW34A8K+99S%]_L=^E;_P!@/%G_`)157^!:#L_#?3CX&\>K]%Y3P=Q( MP-BG(\(TD&41=:-CV"@+%'-99H=A)MVN5%%BG2 M,!SG$W8(Z#5'EGPW'1FS#-NK%-\-*Q4Y5ZJ==W_-A<+_`(XC%EU5/.*JE@ZM M9F$*V$YOW*33H[X*EVE@J?"C'EAFX]9-PR>Y/D[7E--LX2 M,!B+)QUYG9J)%0!#]TW,`!\G;H-Q,-7(6M1<;`UB)B:W`0[4K**@8&-:P\-& MLR$[J36/C(U-JS8MT```(1(A2@'8&V@U[\ANC_TSN5UY?Y.Y`\-\-9!R+*G* MI+W52"=5VQ31R;`16B]GUF"BR9#F0,X%(YR@(EW`-!W+ MFGCW@_D?2'V-L_8FQ]F.B/\`OBM5\B52&M$4FJ<``7+-&2:*GCWW9V.&YDEB M_N3!H-,]J\,+T5;7-FG%>(XP)U%E%SQ=5RIE:`A.\H;OBF2,9W`$$T2>0I"= MTI0[`T&?7%#I8=/KA"Y2E>,?%?%6-;0DB*'X=)P0V3((E$-C=R\6MQ-V-MWP M`.\"*Z8&`.T!W'0?/;XCD1R?XWU;,^48.E,*#'R%PE;.M!EKL2 M_D9.,;.JRPFF,*_6:/95O5^"G%F(=Q+ MMK(1;Q'#=.6?1\@R53<-'K5^ZC5WB3ILX2*H10IP.4Y0,`[AH-@8`(".X[^3 M;LVV#M';?<1'81[/L!H.8GD^W]P-!^]`T#0-`T#0-`T#0-`T$'+JS?\`NQ>D M'^3["7YV>0&@G&Z!H-775PZ7.'^J]Q/L6!<@`QK>1H'TVU8#RX+$'4IBW)1& M8HM7AQ2`';ZFV4B9&4_'%-W7C(04)W7;9HNB%.!R7XW9BXAYTR3QQSY4'E'R MOBJQNJW:H)WNH@95("+Q\S#/P*5"9K5AC%T7T:^1W0>L7"2R8B4X:#HO06U' MA,?U*F"_RI<@_P`[%BT$E#0=(\F?^F_D#^1'*W_`<]H*'70;5^AM^M]Z=?Z4 M^,?XW#074.@B8VKCA&X>\7/AK+\%&MV$9RBX+9$OTRJV0!!)W?Z/6I?%]B4, M4A"I'=*5NK0:ZQ@W,=1P)S_2,(B$L[0:_>H/S_I_`2J8`DYFEOL7C94IDG#5VV5,FH0P"4Y M#"`AL.@I*>K%PIDNGQU!>2_%Q5H[0JM+O[Z:Q6\=%4'ZVP_=B$MN,WI7)Q,5 MZX;527;LGBA3"4)!HX3'8Q#``8$5:SS])L]5AI5BN7M1>1TBT362,':4Y`'06`'ATH?*'5KZJO*KK5 M,<30C,SAW6*_DZQT-A3S,ZHH]3_\#'N(F"_I!.Z0WIEK2<_^((B(3V]!7:^- M2X/?@UE'CCU`ZE#^;BLEQ"O'C,;QJB8J)+O3V[^SXLFI`Y2B51_8Z8>6CQ4, M(=U"NMR=NX:""CH)(/A],+Y6ZE'41X.8/RI,2=RXV=/6)NN\]VF**Z27,8RL>98A0%-$"E"VWT#0=2Y]LDU3<$YJM]; M>C&V*JXER/9("1!%NY%A-0=.F9.*>@W=I+M7`M7S5-3N*D.F?N[&*("(:#6C MT&>+:M65YQVV45*F><:MFSF.`2B^;`B M4[XP1.]!9[>"[R?8[;TU<4,<(^%N>/<>VM[%(%,80 M2;DLKE^[V```5'IQ\HCH)@6@:#A5W[-OL"'[6L41,ZFF?V8IGY88K\S%J8CY MTRUK]4[G[5^GAQ2N68'BC*0R5/E7I6$*DZ5)W[)D:49G*Q76;@`J*0581,,C M('VV!%#S>_>5)KW/0/1E[K+J*WH;<3]WIKIJN5=D48\,>^K./1$SV/-=:]1V MNF-AKOS/\Q7;JII[^;#*?5^I5O6RVV:^VFQWBYS<<\YX\INBQA7E)U?5H-93LNKJ^IN3$4XSE'9''Q3 M_.\43!V["4P@("(!_E!L'SCMJ'U-//33:_:HG&?CA**NJ+43$SE-./R,6N9W M+''G"CCIDGD7DUXFG`42&.>+ARJE)(6ZW/\`O-JO4HD##]-].2IB(]@"*:8G M4'Z)!UWW3G3^IZMWRC9M)3,US.<]E,=M4X=W#TS&+I-ZW>QT_LU6Y:F8PB,H M[YPRB/E^%53\@\[9#Y.YGR3GW*\G]:WW*-H>V6:4(90[2,*X,=&*KT80W?(U MB*_%))-&J8=T`32W#[[M^ANP[3H>F]NM[7HZ(IMTT4QEX1$9SW^/>A-O.Z:K M?]SJU&HJFJ)JFU4QP@#M$/V0_;U6NGGHF MB.,Q,?"MF>6,>Y^C%$!$!^7L'M[#!V#L.W8(;@`_:UQ[=OW-'NJ\Z5::^>CG MHRJ;ONA9U(C\#N4C>FW^:.UXY<@GD15,B>DJ*G84JWG5]#IN1RIB!B((LG#D M6MT=$3N&FB:HPXS&&=/KB,NZ<);2\K^K M;VS;C&FU-4_=+E6&?V^5C8QV]CZI%.8QA)3[QNF=5O%1TA..XV';NWO<[A3.5T MD"F,'>4*7<0#"O@%SVJW4*Q9;W8J*KD_\#"/YNWT&4

./4'BN2/*+DUQ6AL#9?I%K MXERT!!Y=N-N>XU6I;:4N46:P49I`*5RYS,]-C::Z3TLABLB$:E'N+B10!+H/ M=Y%YY0,5R!GN*>"<37_D[R`I%9@[CE.J8]>5.LU+#=?M":JE4-E/)E\FX&JP M,]:T6RJS"';&>RJS8HK"@1+8PA[7"/.6GY0S=9>+N0L?7WCOR@U<%?1RHE]);)@8HB'JLH\[(^N\ MBI/B3A+"V1^27(&JT"OY1R+6J9(TRE5+%U*MCI\SI[V_9"R+.P$$SE;@XC'' MH$*(HF4.1,GTM!V+QOY1NL^2.8:A8<-9%P=E+!5FAZS?L=9#<52165" MSU].SU6R5.TTV:L%8M%6L,4K^\.DG*1DUDE4UDTS$$!#$;'/5.FLOY3Y(8?Q MEP6Y17"X<3[['XXS4V83W'EDC#V29@B6>$3@E)K,D:%D;2U>53LR8Q3XW93L>#\J MV+(\CC`(R(RU6&UKMHM#$_HCI MXR;[-A*J<"D,&X9KX/Y6SF3\MV'".0N.N8N/U[AL<1N4HI/)+W&TY"6VJNK$ MYJK]2!G<:W6X,2R<+,))E=-70MUP2<)*%*)#"(!\CF+J&8-PES7XT<&+D,TE MDWE!7[?,T^P-T$#5&OR-=:O'M?J]F?'5*HUL&14H25+#(E*(K&C%MPVV'09I MVF5E(2M3DS!UN1N$Q%Q;M]&U2)>14?*6!XW1%5"(8O9UY'0[1X],`$(=TNBB M4PAWS%#MT&&?3_YV5CJ#XCG\UT/%&3<8TF'OULQNQ4R@I2"2E@LE!G9*L74L M1.D=RWCX^+BHAF!WDI,3,F]1;-4"``JKJE#O%#<=!B$[Z@>2ZHP MQU=\L\&.06*\-9)NM`I+/(\K;,)6.3I;K*%@BZQ39K)F.:S?I&VU2`*L?/`*Z9``W=#9D7<-P,8#"4P@(@&W;Y=OV`W[/F^??0>%!,!#"4`$P M`.P"(%#?YQ$!``^SH-=W-[J%Q?!N7PPRM_'W,638G/65*9@W'ECQP^QH,>\R MW?UGR-7J$JSM=WKDM$%?`P.87ZB/H)`^^4`=@$/N>7G,O^IOQH<\F[Y@K+ET MA80:\6YX^QD>CV'(-5/97[2%9H%CG5ICHZTO$9V209BA$.GJRJIRBF4Y-QT' MWF`^5N-^4_&RK4H^1-$53`!!*(ACCC7J-2?)**EKWP\XHY MGY&83BI:8B(S.!;!C#$E$R2X@7CN,E7&(&^3[9"6>]PZ$BR.BE)"P81CHP"* M#A0GTM!EYQHY!57E!AVM9CJ,):JJPG7=FA96GWJ/:15UI=LI-KG*1<:C:XZ/ M?RC%I-0%FKKI!0$7*R2A"E53.9-0@B'?Y/)]O[@:#]Z!H&@:!H&@:!H&@:!H M(.'5F.0/%C=(0!.0!#'^$`,'>+N43Y9S^!`,&^X"<>P-_*/DT$X_0-`T$9WQ M&G0^A^IQ@H^<\%U]@RYP8*K;P]*5;E;LC9RH#$SB3?X:L+LXI)GFT5E5G56> M+F[C:055:*&3;OE%VX5/4O$2U?EI2!GHR0A)R$D7L1,PTNR0Y&M0[R[5."M0-0LT-7;.X9J34-%V`&2/IB#=9-)SYHOG"F MV#0?4S,S$5V(E;!8)6-@H&"C7TS-SR4K*R3U5!E'QL>R0. MLNNL)?Z>N.,-2*\[Q+XBY@FI/%+\A7!8[(% MCQI!S.5L@9F!DL!13C+'*8XCF$.*A0.,3'-W`E24=K)%"PWT#0-!!#\:?P5& MP8_X[]0VFPOG)*@/_P"KKFQXT;E%4U/LKJ1LV);!(F(4HD90-L/+Q:BQQ,)E MIUFD&P%#05Y35JY>N6[-FW7=O':Z35HT:I*+N73E=0J2#=N@D4ZJRZRIP*0A M0$QC"``&^@NH^B[P3;].OIQ\=>.C^.18Y'"LER1FY4A2^?=YER.1"PW1JZ6* M``[_``4%9O`-U=@$[*(0[-!M.T&L7K(<)D.H'TX>3G&]I&I2%[EJ*YN^'S&( M`N&V8,<'+<:"BT6'M:C896*^IG"@;CZ%)+EV$#"&@I1G#==HNLU=(K-G+991 MNX;N$SHKMUT3F361614*51)9)0HE,4P`)1`0$-]!9V>#BX0_S(<$\@\P;5$> MBWCE_>CMJFY=-A(Z;X4Q"[EJU`G0,L`+($L=_=3[E3N@5-RU;,E/I`!!`)@^ M@:#HGE)_TR\B_P`A.7?S?V'05K'A0.K)7.%/)JR\/\[VAM7./O+>8@_P7LTT M]39U_&_(-BD2%K@YMRK2J9)`N+D)"J56]ST%77P.1$1 M<`[B&"*G?W'O][?Y=!:A>%3XAV7BKTFHJ(2#*H6 MF+KM3QKZ210"B"EG9&-AF#F9F'S>,BXAH M[DG\B]7*V8,&3-NJX>OGJZABHHMF;1(ZASG$"$*43".P:I]WNZFNFSIL]155 M$1';..6$>O!QM1?HTU,W;LX6HB9E6*=9/J*/>H5RVG[-791RI@'$H26/L&10 M+&(TD(IN\,6?R.LV_P##&2O,@@"R1Q#ODC4FZ0_NM3N\J^CJ>CNG:-3Z3OI_P"5_@TS.6[W M2Y6[M9LN@LR=KLGJ"Z#ED]:+*-G3-VW5*LU=MG"0E4;N6RY"G(3 M7(IMVM1,::O#DN4DY<9BL3TRQLA:@WJ62TT"@*AVMICD`(\.4O=3D45^T`,74$?-7H>_ MT;U/=^[TX:+43-5$]F,YU4^KC'AEV)H=`]2V.I]EBC53'WFW1G$]L1E$_K]2 M+9XAGJ0%Y:\DS<<\83P.<"<:)E_%+.8USWXR_9B2*LQLUB$R1C-I"'K!#?5K M$=SE$Y'"A1W.&M^^1?1%.Q;+.,^/H:5\W.L)W35 MQL&DST=G*9B>/9_A/Z8H\'G$Q[>\';]@!V^U\VMU3.,XM'2U+/W8Q^<-Q,B5LH.XF,.H3^9+5O5+?Q MT=9-ED9-/-,YZ<]5M2>6J>5=!T<^Y$C,2"F`=WOF\N@[[Z1T3D"%ZH/7&C,I M7*!O][;9/X@ISUMK=1"AP\P<,&K*M%FE2^OK,:**E'J))F`7S@55"&.(AOMH M/M>CZJ:+YC=8II)BI-U28$(IP M5U%.U#"W%3Z`%*`[A@GP=1Y8..HSUV$N-DAQYBT%N6^&$9E_F^(R1-.&DF;C MY7`:N(F-HTE#(.V237O&.FX$QMBE[>T>W0;[53LFZAI%R MD@D=!J"*CU5),HH,P[KER)W1R@8C1/M.?M!/8F_R;@$0_EI'YBY6<6>5O+#& M'&_DA.Y^4Y-5CE]PIS/`P>/G-$BL>\/WI8K"36/>N\C1]L0K5]I<58WSQ-.- M[[H;,(E35*("8)-7#?DS3^87&#`W)RC+)J5S-V-ZW=T4$=Q^J91_'D)8:XY[ M^RB;RNV%)TR4*?8Y3H"!O)H-6WASS=WIRNQV$W>Y=2;AG6O\`45Z;]$M-&J%Z MKF::PVKO+S"-#L-EAJG"3D%?X=0\!F5G5GSUN0"2+4C]0H%$@;@*A0DSL'S= MVU8N4/.G1DD$'38QB"!_,N6Y'"!G!3]TZ*AT.T0$/O@$/+H/9?)O\V_V>SR_ M)OOH-!O7B'SD=TLC%W$$^KEQ'*;8IA$#`O;.S8H"._9H,X>J:J)>'5B.D)@4 M2S3Q;,40*8!`R?)W$H@(#MV[&)Y0WV\ODT&N_*K%?HQ9@L29AD%DV-K\V";6/E#INQ[I3[`' MM$HN_P!N\.=EN+PZL\D;O.\,>31:Z\<2,2*A4% M$1$JQCE,01`P"(9[=)>T8YMG3-X)RF)E8\]'_JP8EBXU*)\TFV8R,+48Z(L< M\)EO2E#><'O]X`#LI(1$H")1*(]HE- MMWB[@`[#W1,&_P!O0NGTQ^G]=KGBCD9R&&+S3 M1H^&D)C#=1H.0+E>SA8X%C9Z\V1-$5L]2:KS$'*-G"1GDJT0*1+8*W%W16/6.U@1-ARY-<>%@+Y5*Y.4>P1SJ;<@BT=*.V*ZJ1B'7;-C&,F4)$V@:!H(& M/BJNA.>U,[AU1N(]/`UCBF9YCF)C"N,/WR?B&:)06Y"UV,:)[GF(=LF`6])( MHBY:%"6$`41D5EPV_>$Q_4J8+_*ER#_.Q8M!(,RWEG'>",97K,N7+2PI&,<: M5J4N-ZM\HF\6CZY6H5N9W*2SQ*.:O7RB#-N03&*DDHH(!V%$=!%/ZK/BB^FW M"<0\]8JXEY8DN1^>H"E4QY?J](5=>YVJV7FOU5FNVK3&35 M>(-(TK]PZ=HI(G*BDH==,*OO0=P.8\J3E,IR&40.3*B4'1HZ0G8:K2B;!5P`BF55L91,@@`B<0[PA\ MCD3QPN/$(MR3$W3]NV-V\2(8=^X5P@)P M#;O%WW`(SO4K\0KU#^II"2.-?*54K$BA2F*&='@Z,6'O/5JD;R=KYUIA;C%ENY%=" M7*55YQ<.N1/%"X`V2 MC(Z/DR``#WCM0#Y=!6#>'1Z9MK MY&]8"%I>9*8.6:@=NTOV)K4-;335-#4V!8P31V[!,.ZI(/R,O/N5.TRKA0YS"(F$=!V_H&@Z) MY2?],O(O\A.7?S?V'04T/#3I#=1GJ`TJRY(XF\8+?E#']5=.XV0NJTU2Z+5W MTVQ216>5^MS>1++5(^U3S-)PF*[6-4=*-_.$!4""<@&"47P%\1-SCZ3!JQPN MZR?&+/LU2:>U:0%$RA.5UU#YXJU88@W;,6+@UO5BJOGNF13+8K22;RR,@BW+ MW?2GY0222"3+2_$S]$VYUA&RCS4A:F8S?S[JNW3%V:(2SL#@`=]JM&DQX\2> MN"".W_DEG29MMRG,';H-&_55\7'BNPXWM''?I5P>0,@Y:R0Q=TQ#D5.5*7JL M33$)U)6,6>XCH\HV3O5KR`JFL)8YQ(,(QM'N#$7(D],4$@#7ET-_"ZYKY!7Z MFW::I)!BVO%?0/DUN2]_^A.K;M_WWW3;J:<,J8IO MB/?8_&U;^2W3//[RJ_K)KQQQQM?9//NJW3_\`Z4.3GX[4[^0>J?W"=7?A M=N^A=^V9OR/=5NG_P#THVVP@%UIH;_;"A@/;K#/G_`-6S_P#&T$3S8_-N_!_ZO`M^2_35N9F+ M^LPF>&-O[-D-QO\`#_< M%!L>CE22DHM82NHYR`><8NR%43V'??I^I?.'>NJZ+5&ZZ+;YBU735&%-WC3P MQQNR[_9_+K;-CN7+FAU.KCWEJ;`1S"=3*7)Y10 MYC'455O%056654-WU5EU5**=199901.'?];\F#I*_)OIVY'U?CVXOS[JMP`_I M0Y-_CK3?Y!ZY/]PG5OX7;_H7?MF/\ENF?W^K^&W]F\>ZK=/_`/I0Y-_CK3?Y M!ZK_`'"=7?A=O^A=^V/R6Z9_?ZOX;?V9[JMT_P#^E#DW^.M-_D'I_<)U=^%V M_P"A=^V/R6Z9_?ZOX;?V9[JMT_\`^E#DW^.M-_D'I_<)U=^%V_Z%W[8_);IG M]_J_AM_9O/NJ_``/_P"T.3?XZTW^0>L4^?\`U9,U5?==!C53A\V[EZ/K>)/D MMTS,8>_UF'_=;^S=_<7?#V<5>(&=*#R$PSFCDM%7N@22KMF1]<*DZAYR.?(B MTF*Y8F:-*;*2,#,L3"DNCYP@[`4Q!*/MUF=*R%IF81262!Q&+6>36,Y?%*<4UE_I=TO:&@]/@? MIY84XZ\ALX*O6Z?D&PX/R@YJT9D&%IR;M"K&N%0FHNRU& M4F(!H^40:R(,DWZ:`@GYX2%*4`^YXY\.<-\8$LB/\>(VN:OV8)QK9LO9AR/; M96_92M69"7O+$Q;ZY>K2T8)1,58Y2`?M2,DI:#B$2M69T/-% M0;@!.Z(`&P9M3\*,]!RT(,I+POUK'.H_ZX@'OU=.QGI2)D?3XB0\RL#*2;=[ MOI*]PW<.`#L.@PAXG].C"W#.Y95N^(;QGJ0D,WW*9R/E2+R-EN9OE?N.1Y]) MBWD[[(QU0K>/\\S^6DJ15[/ M"W5G5\=9%DZ%%/[=6)1M-56Q3)(EN+B2D:S*M2+LN^H"2:@;B0W9L'>%JP=$ MW+"$W@B=O&4%8&Q4IS0YF[,[J\CLJ/(=\U.RD'GX=,6Z$@WGG[)0R2CU(J:_ M=,(E$IMC`'\^,<`53$6!:IQVIL_>$J32*$ECBLS,K9#2]XC*VTC%(>-\W9GC M,ZJLG$1IRI-G"B9CD*F7?O"`[AT/Q1Z>N$N%>"+?QSP!9\TUO&]LE[)/MDY7 M*4S89ZCS=O\`.KV*3QW-2B*Z]17DI1PH_,1`HH$?*G5(0IC&W#IC"G2-P9QR MI!L;X-SUS3QI1CV&SVP]:K?):T)QQK+([GA1*0ULFL*/4':D@M*7FQJY&?V)[=5LD.+VYR4W=MK M7^'YKZM];%ER."NTWA2F*8`*`:#K5YTRR0=OJ.,,] M9@=6W&Q+/5W0/ZM.VJLQ,-729$?UM^FFNS&PJ2:::Z1%1*90H'T'C9W([I]DG(0]I;4]O*HO:-.,(MXSC9V!M"3\$'*4@1P MW23$RA4A5`@E#+,Z7>`2[]T![`[H]T0`/(`;!V;;:#`SE]TZ,).:[D)K&P[8#*VN+.^4*FLJH=/NCMYOM M'<.P\_\`#FA\E<-P&#\E9`S62J0 MRJK2P1;9^/=!$#ND"F$.[N40[*>`\8<:\2-I=M MBW$-2:TBFL;'*JV&62KS([D[9G)RKQ,%9,4RNC$[RA?I$``'?08?P?2@X_8\ MGKP^P+DOD[QEIN2IZ0L]XPYQ_P`YS]#P]*6"94.M.R\'2SLY9+'K^>75.=XI M6UH@RQS";<#;&`,SJKQYQ50L*N./E`K847%JU2GZ:G#U1^_BI)I'V=K(MYZ4 M;V$BYYLUJE'$JN\7EE5U)!9\H+A14RHB80]E@7"U3XZ8;QU@VB/K7)T_&%98 MU2NR%YL\G<[>[C8_O^97L-IF5%9.;DCBH/?76,)A[`[```T';F@:!H&@:!H& M@:!H&@]"^JM7E')WLG6X"1>*@0%';Z'CG;E0$R%33`Z[ANHJ<")E`H;CV``` M&@_C_`6D?[G57\7HC^!Z#]ITFF(J)K(U&L)*I'*HDJG`11%$U"&`Q%$SE:`8 MAR&`!`0$!`0T'T^@:!H.!TU;/FSAD];H/&;Q!9J[:.D4W#9TV<)F27;N$%2G M27072.)3D,`E,41`0$!T'3?'_CC@WBKCAIB#CMC*KXBQBPFK#86%(IS15A7V M$O:I9S.3[IBR467*S+(2CM144DQ*BGWNZF0A``H!W(Y;-GK=9H\;H.VKA,R3 MALY237;KI'#8Z:R*I3)JIF#L$#`(#H/G/P%I'^YU5_%Z(_@>@?@+2/\`@?@+2/]SJK^+T1_`]`_`6D?[G57\7HC^!Z!^` MM(_W.JOXO1'\#T'L8VNU^&547AX*&BEE4_-*K1L8R8JJI=X#^;44:H)'.GWR M@.PB(;AOH/CC-)G)= MEAR298Z7LBYE5"+.6QYIXILF5,AEW:RI@%54YS!WYH&@:#H6]\7N/F3LTX>Y M%7_$U0M>;^/Z-J;X;R3+,#KV2@(W6.&*LR<(N58B&TDQ,8@>>35%`QC'1\V< MQC"'?6@:!H/3V&OPUL@)RK6./0EJ]98>3K\[%.@,+:3AIEDO'2D>Y`AB'%!Z MQ$LL?)1JI@*(@`BD(AH-94_T$NCE99-:6D>GIQW;NUSB M=1.!KDC58X#".X^:AZO+P\0@7?Y"(%#098\>NGMP8XGNB2/&_B3Q_P`-S9`$ MOX3TC%]4B[@&`?ET&8F@:!H&@:!H&@:!H&@:!H M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@UK=5SB7/[G9?^)6R[ZWM'MGZ![N=E_XE;+OK>T>V?H'NYV7 M_B5LN^M[1[9^@>[G9?\`B5LN^M[1[9^@>[G9?^)6R[ZWM'MGZ![N=E_XE;+O MK>T>V?H'NYV7_B5LN^M[1[9^@>[G9?\`B5LN^M[1[9^@>[G9?^)6R[ZWM'MG MZ![N=E_XE;+OK>T>V?H'NYV7_B5LN^M[1[9^@>[G9?\`B5LN^M[1[9^@>[G9 M?^)6R[ZWM'MGZ![N=E_XE;+OK>T>V?H'NYV7_B5LN^M[1[9^@>[G9?\`B5LN M^M[1[9^@>[G9?^)6R[ZWM'MGZ![N=E_XE;+OK>T>V?H'NYV7_B5LN^M[1[9^ M@>[G9?\`B5LN^M[1[9^@>[G9?^)6R[ZWM'MGZ![N=E_XE;+OK>T>V?H'NYV7 M_B5LN^M[1[9^@>[G9?\`B5LN^M[1[9^@>[G9?^)6R[ZWM'MGZ![N=E_XE;+O MK>T>V?H'NYV7_B5LN^M[1[9^@>[G9?\`B5LN^M[1[9^@>[G9?^)6R[ZWM'MG MZ![N=E_XE;+OK>T>V?H'NYV7_B5LN^M[1[9^@>[G9?\`B5LN^M[1[9^@>[G9 M?^)6R[ZWM'MGZ![N=E_XE;+OK>T>V?H'NYV7_B5LN^M[1[9^@>[G9?\`B5LN M^M[1[9^@>[G9?^)6R[ZWM'MGZ![N=E_XE;+OK>T>V?H'NYV7_B5LN^M[1[9^ M@>[G9?\`B5LN^M[1[9^@>[G9?^)6R[ZWM'MGZ![N=E_XE;+OK>T>V?H'NYV7 M_B5LN^M[1[9^@>[G9?\`B5LN^M[1[9^@>[G9?^)6R[ZWM'MGZ![N=E_XE;+O MK>T>V?H'NYV7_B5LN^M[1[9^@>[G9?\`B5LN^M[1[9^@>[G9?^)6R[ZWM'MG MZ![N=E_XE;+OK>T>V?H'NYV7_B5LN^M[1[9^@>[G9?\`B5LN^M[1[9^@>[G9 M?^)6R[ZWM'MGZ![N=E_XE;+OK>T>V?H'NYV7_B5LN^M[1[9^@>[G9?\`B5LN M^M[1[9^@>[G9?^)6R[ZWM'MGZ![N=E_XE;+OK>T>V?H'NYV7_B5LN^M[1[9^ M@>[G9?\`B5LN^M[1[9^@>[G9?^)6R[ZWM'MGZ![N=E_XE;+OK>T>V?H'NYV7 M_B5LN^M[1[9^@>[G9?\`B5LN^M[1[9^@>[G9?^)6R[ZWM'MGZ![N=E_XE;+O MK>T>V?H'NYV7_B5LN^M[1[9^@>[G9?\`B5LN^M[1[9^@>[G9?^)6R[ZWM'MG MZ![N=E_XE;+OK>T>V?H'NYV7_B5LN^M[1[9^@>[G9?\`B5LN^M[1[9^@>[G9 M?^)6R[ZWM'MGZ![N=E_XE;+OK>T>V?H'NYV7_B5LN^M[1[9^@>[G9?\`B5LN M^M[1[9^@>[G9?^)6R[ZWM'MGZ![N=E_XE;+OK>T>V?H'NYV7_B5LN^M[1[9^ M@>[G9?\`B5LN^M[1[9^@>[G9?^)6R[ZWM'MGZ![N=E_XE;+OK>T>V?H'NYV7 M_B5LN^M[1[9^@>[G9?\`B5LN^M[1[9^@>[G9?^)6R[ZWM'MGZ![N=E_XE;+O MK>T>V?H-TU?Z9MSB^C3>>!)^J+ -----END PRIVACY-ENHANCED MESSAGE-----